OR WAIT null SECS
Click here to read the articles and download the PDF
A conversation with Matthew Bardell, managing director, nVentic, about a perhaps overlooked but useful strategic component of company performance and overall business benchmarks: inventory optimization.
Making sense of the accelerating trends and challenges—including store closings, pharmacy deserts, and the rise of polypharmacy.
Even as pharma technology evolves, and payers argue over reimbursement practices throughout healthcare, drug wholesaling is a thriving business.
December 28, 2023
Over the past year, Pharma Commerce’s digital coverage featured a variety of subject matters, ranging from how to calculate 340B prices, to the future of pharmacy.
December 27, 2023
The most popular pieces pertaining to the supply chain featured ADMs, vaccine supply chains, and wholesalers.
December 26, 2023
Items in this sector ranged touched on topics such as pharma shipping, container technology, and sustainability.
December 25, 2023
This year’s PC Podcast episodes ranged in topic, from DSCSA compliance to pharmacovigilance.
December 22, 2023
Camille Lee discusses the impact of commercial availability of Bimzelx for the treatment of moderate-to-severe plaque psoriasis in adults, along with the value of patient assistance/affordability programs.
December 21, 2023
In the face of chronic disease, DTx have the opportunity to provide a lifeline to patients.
December 20, 2023
A panel designs a conceptual framework in an effort to limit partiality.
If the FDA approves the sBLA for Xolair, it would be the first drug indicated to lower allergic reactions to multiple foods after an accidental exposure.
If the FDA approves garadacimab, it would be the first approved hereditary angioedema therapy that targets activated FXIIa.
Filsuvez is indicated to treat wounds associated with junctional epidermolysis bullosa and dystrophic epidermolysis bullosa in patients aged 6 months and older.